Block Listing of Shares

Hikma Pharmaceuticals Plc
08 October 2007



                            Block Listing of Shares


                           Hikma Pharmaceuticals PLC


LONDON, 8 October 2007 - The Board of Hikma Pharmaceuticals PLC ('Hikma') (LSE:
HIK) (DIFX: HIK), the multinational pharmaceuticals group, announces that it has
made a block listing application to the Financial Services Authority and the
London Stock Exchange plc for a total of 2,432,400 ordinary shares of 10p each
in the capital of the Company to be admitted to the Official List of the UK
Listing Authority and admitted to trading on the main market of the London Stock
Exchange.

The shares, when issued, will be issued fully paid and rank pari passu in all
respects with the existing issued ordinary shares of the Company. The shares may
be issued pursuant to the exercise of options under the Hikma Pharmaceuticals
PLC 2004 Stock Option Plan (the 'Plan'). Participants in the Plan have or will
become entitled to these shares following the vesting and exercise of options
over shares.

It is expected that admission will be granted on 11 October 2007.

For further information, please contact:

Henry Knowles, Company Secretary
Hikma Pharmaceuticals PLC                                 [phone]

Susan Ringdal, Investor Relations Director
Hikma Pharmaceuticals PLC                                 [phone]



About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed products. Hikma operates through three
businesses: 'Branded', 'Injectables' and 'Generics', based principally in the
Middle East and North Africa ('MENA'), where it is a market leader and sells
across 18 countries, the United States and Europe. In 2006, Hikma achieved
revenues of $317 million (2005 $262 million) and profit attributable to
shareholders was $55 million (2005 $44 million). At 31 December 2006, the Group
had over 2,400 employees. For news and other information, please visit
www.hikma.com.





                      This information is provided by RNS
            The company news service from the London Stock Exchange